Study Name: Precision administration of anti-thymocyte globulin with or without verapamil in type 1 diabetes
Principal Investigator: Laura Jacobsen, M.D.
What is the Precise ATG+Verapamil T1D study?
Researchers at the University of Florida are studying whether a medication called anti-thymocyte globulin (ATG) can help protect insulin-producing cells in people who were recently diagnosed with type 1 diabetes (T1D). ATG works by calming parts of the immune system that attack insulin-producing beta cells. In this study, researchers are also exploring whether adding a common heart medication called verapamil later on may provide additional benefits.
The goal is to learn whether ATG works better in some people than others and whether verapamil can help preserve insulin production after ATG treatment.
Who can participate?
- Participants who are between 6 and 35 years old
- Were diagnosed with type 1 diabetes in the past 100 days
- Weight at leas 30kg (66 lbs)
What will study participants be asked to do?
Year One
Participants are randomly assigned to receive:
- ATG or Placebo (inactive treatment) (50/50 chance)
Treatment is given by IV infusion over 2 days. Participants have regular visits, blood tests, and meal tests to measure insulin production.
Year Two
Participants are again randomly assigned to:
- Take verapamil pills or receive no additional study medication (50/50 chance)
Participants continue their regular diabetes care throughout the study.
Why Participate?
This study may help researchers develop more personalized treatments to slow the loss of insulin production in people newly diagnosed with T1D.
Interested in Learning More?
Call (352) 294-5760 or email our Study Coordinators: